Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 3c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Zimmer Biomet (ZBH) PT Raised to $132 at Oppenheimer Following 4Q Report
February 1, 2017 10:51 AM ESTOppenheimer raised its price target on Zimmer Biomet (NYSE: ZBH) to $132.00 (from $126.00) while maintaining a Outperform rating.
Analyst Steven Lichtman commented, "4Q16 sales of $2.013B (+3.0% organic, ex-stocking/FX, day-adjusted) were in line with ZBH's above consensus pre-announcement earlier in January; recall Americas... More
